Skip to main content
SpringerLink
Log in

Surveillance of the Patients with High Risk of Hepatocellular Cancer

  • Review Article
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Singal A, Volk LM, Waljee A, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009;30:37–47.

    Article  CAS  Google Scholar 

  2. Ferenci P, Fried M, Labrecque D, et al. Hepatocellular carcinoma. A global perspective. J Clin Gastroenterol. 2010;44(4):1239–45.

    Article  Google Scholar 

  3. Davis GL, Dempster J, Meler JD, et al. Hepatocellular carcinoma: management of an increasingly common problem. Proc (Bayl Univ med Cent). 2008;21(3):266–80.

    Article  Google Scholar 

  4. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42(5):1208–36.

    Article  Google Scholar 

  5. Intaraprosong P, Siramolpiwat S, Vilaichone RK, et al. Advances in management of hepatocellular carcinoma. Asian Pac J Cancer Prev. 2016;17(8):3697–703.

    Google Scholar 

  6. Lın COS, Keeffe EB, Sanders GD, Owens DK. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. Aliment Pharmacol Ther. 2004;19:1159–72.

    Article  Google Scholar 

  7. Ting S, Shih F, Crowley S, Sheu JC. Cost-effectiveness analysis of a two-stage screening intervention for hepatocellular carcinoma in Taiwan. J Formos med Assoc. 2010;109(1):39–55.

    Article  Google Scholar 

  8. Andersson KL, Salomon JA, Chung RT, et al. Cost-effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 2008;6(12):1418–24.

    Article  Google Scholar 

  9. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer res Clin Oncol. 2004;130:417–22.

    PubMed  Google Scholar 

  10. Mcmahon BJ, Bulkow L, Harpster A, et al. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology. 2000;32:842–6.

    Article  CAS  Google Scholar 

  11. Stravitz RT, Heuman DM, Chand N, et al. Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. Am J med. 2008;121:119–26.

    Article  Google Scholar 

  12. Kuo YH, Lu SN, Chen CL, et al. Hepatocellular carcinoma surveillance and appropriate treatment options improve survival for patients with liver cirrhosis. Eur J Cancer. 2010;46:744–51.

    Article  Google Scholar 

  13. Yeh YP, Hu TH, Cho PY, et al. Evaluation of abdominal ultrasonography mass screening for hepatocellular carcinoma in Taiwan. Hepatology. 2014;59:1840–9.

    Article  Google Scholar 

  14. Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 2016;150:835–53.

    Article  Google Scholar 

  15. Bolondi L, Sofia S, Siringo S, et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut. 2001;48:251–9.

    Article  CAS  Google Scholar 

  16. Yang HI, Yuen MF, Chan HLY, et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol. 2011;12:568–74.

    Article  Google Scholar 

  17. Michikawa T, Inoue M, Sawada N, et al. Development of a prediction model for 10-year risk of hepatocellular carcinoma in middle-aged Japanese: the Japan Public Health Center-based Prospective Study Cohort II. Prev med. 2012;55:137–43.

    Article  Google Scholar 

  18. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–2.

    Article  Google Scholar 

  19. Yeoman AD, Al-Chalabi T, Karani JB. Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: implications for follow up and screening. Hepatology. 2008;48:863–70.

    Article  Google Scholar 

  20. Benson AB, Abrams TA, Ben-Josef E, et al. Hepatobiliary cancers: clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2009;7(4):350–91.

    Article  CAS  Google Scholar 

  21. Omata M, Lesmana LA, Tateishi R, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010;4:439–74.

    Article  Google Scholar 

  22. Balogh J, Victor D III, Asham EH, et al. Hepatocellular carcinoma. A review. Journal of Hepatocellular Carcinoma. 2016;3:41–53.

    Article  Google Scholar 

  23. Wong VWS, Chan SL, Mo F, et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol. 28:1660–5.

    Article  CAS  Google Scholar 

  24. Flemming JA, Yang JD, Vittinghoff E, et al. Risk prediction of hepatocellular carcinoma in patients with cirrhosis: the ADRESS-HCC risk model. Cancer. 2014;120(22):3485–93.

    Article  Google Scholar 

  25. El-Serag HB, Kanwal F, Davila JA, Kramer J, Richardson P. A new laboratory based algorithm to predict development of hepatocellular carcinoma in patients with hepatitis C and cirrhosis. Gastroenterology. 2014;146(5):1249–55.

    Article  CAS  Google Scholar 

  26. Yang HI, Sherman M, Su J, et al. Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Clin Oncol. 2010;28:2437–44.

    Article  Google Scholar 

  27. Yuen MF, Tanaka Y, Fong DYT, et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol. 2009;50:80–8.

    Article  Google Scholar 

  28. Jung KS, Kim SU, Ahn SH, et al. Risk assessment of hepatitis B virus–related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). Hepatology. 2011;53:885–94.

    Article  CAS  Google Scholar 

  29. Shin SH, Kim SU, Park JY, et al. Liver stiffness-based model for prediction of hepatocellular carcinoma in chronic hepatitis B virus infection: comparison with histological fibrosis. Liver Int. 2015;35:1054–62.

    Article  CAS  Google Scholar 

  30. Chang KC, WuYY HCH, et al. Clinical-guide risk prediction of hepatocellular carcinoma development in chronic hepatitis C patients after interferon-based therapy. Br J Cancer. 2013;109:2481–8.

    Article  CAS  Google Scholar 

  31. Lok AS, Seeff LB, Morgan TR, et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C related advanced liver disease. Gastroenterology. 2009;136(1):138–48.

    Article  CAS  Google Scholar 

  32. Masuzaki R, Tateishi R, Yoshida H, et al. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology. 2009;49:1954–61.

    Article  Google Scholar 

  33. Chan AWH, Chan SL, Mo FKF, et al. Albumin-to-alkaline phosphatase ratio: a novel prognostic index for hepatocellular carcinoma. Hindawi Publishing Corporation Disease Markers Volume 2015, Article ID 564057, 10 pages.

  34. Wong GLH, Chan HLY, Wong KYK, et al. Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B. J Hepatol. 2014;60:339–45.

    Article  Google Scholar 

  35. Lu SN, Wang JH, Chen PF, et al. Community-based mass ultrasonographic screening of hepatocellular carcinoma among thrombocytopenic adults. Cancer Epidemiol Biomark Prev. 2008;17(7):1813–21.

    Article  Google Scholar 

  36. Kansagara D, Papak J, Pahsa AS, et al. Screening for hepatocellular carcinoma in chronic liver disease. A systematic review. Ann Intern med. 2014;161:261–9.

    Article  Google Scholar 

  37. Chen JG, Parkin DM, Chen QG, et al. Screening for liver cancer: results of a randomised controlled trial in Qidong, China. J med Screen. 2003;10:204–9.

    Article  Google Scholar 

  38. Ungtrakul T, Mahidol C, Chun P, et al. Hepatocellular carcinoma screening and surveillance in 2293 chronic hepatitis B patients in an endemic area. World J Gastroenterol. 2016;22(34):7806–12.

    Article  Google Scholar 

  39. Trevisani F, D'Intino PE, Morselli-Labate AM, et al. Serum a-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol. 2001;34:570–5.

    Article  CAS  Google Scholar 

  40. Lok AS, Sterling RK, Everhart JE, et al. Des-gamma-carboxy prothrombin and alpha fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology. 2010;138(2):493.

    Article  CAS  Google Scholar 

  41. Zoli M, Magalotti D, Bianchi G, et al. Efficacy of a surveillance program for early detection of hepatocellular carcinoma. Cancer. 1996;78:977–85.

    Article  CAS  Google Scholar 

  42. Tong MJ, Blatt LM, Kao VWC, et al. Chronic liver diseases: epidemiology, pathophysiology, diagnosis and treatment surveillance for hepatocellular carcinoma in patients with chronic viral hepatitis in the United States of America. J Gastroenterol Hepatol. 2001;16:553–9.

    Article  CAS  Google Scholar 

  43. Singal AG, Conjeevaram HS, Volk ML. Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomark Prev. 2012;21(5):793–9.

    Article  Google Scholar 

  44. Oka H, Saito A, Ito K, et al. Hepatocellular carcinoma and a-fetoprotein multicenter prospective analysis of newly diagnosed hepatocellular carcinoma with respect to the percentage of Lens culinaris agglutinin-reactive a-fetoprotein1. J Gastroenterol Hepatol. 2001;16:1378–83.

    Article  CAS  Google Scholar 

  45. Coon JT, Rogers G, Hewson P, et al. Surveillance of cirrhosis for hepatocellular carcinoma: a cost–utility. Br J Cancer. 2008;98:1166–75.

    Article  Google Scholar 

  46. Marrero JA, Feng Z, Wang Y, et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology. 2009;137(1):110–8.

    Article  CAS  Google Scholar 

  47. Pocha C, Dieperink E, McMaken KA, et al. Surveillance for hepatocellular cancer with ultrasonography vs. computed tomography—a randomised study. Aliment Pharmacol Ther. 2013;38:303–12.

    Article  CAS  Google Scholar 

  48. Sherman M, Bruix J, Morayko M, et al. Screening for hepatocellular carcinoma: the rationale for the American Association for the Study of Liver Diseases recommendations. Hepatology. 2012;56(3):793–6.

    Article  Google Scholar 

  49. Saab S, Ly D, Nieto J, et al. Hepatocellular carcinoma screening in patients waiting for liver transplantation: a decision analytic model. Liver Transpl. 2003;9:672–81.

    Article  Google Scholar 

  50. Trinchet JC, Chaffaut C, Bourcier VR, et al. Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology. 2011;54:1987–97.

    Article  Google Scholar 

  51. Han KH, Kim DY, Park JY, et al. Survival of hepatocellular carcinoma patients may be improved in surveillance interval not more than 6 months compared with more than 6 months. A 15-year prospective study. J Clin Gastroenterol. 2013;47:538–44.

    Article  Google Scholar 

Download references

Acknowledgements

The author is very thankful to Dr. Favzia Mai Tung for editing this article.

Author information

Authors and Affiliations

  1. Department of Gastroenterology, Ankara University Medical School, Ankara, Turkey

    Necati Örmeci

Authors
  1. Necati Örmeci
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Necati Örmeci.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Örmeci, N. Surveillance of the Patients with High Risk of Hepatocellular Cancer. J Gastrointest Canc 48, 246–249 (2017). https://doi.org/10.1007/s12029-017-9972-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-017-9972-3

Keywords

Search

Navigation